Compare PWP & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PWP | ARDX |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | 2014 |
| Metric | PWP | ARDX |
|---|---|---|
| Price | $18.16 | $5.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $23.50 | $15.14 |
| AVG Volume (30 Days) | 693.0K | ★ 2.8M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 138.52 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $31.87 | $37.75 |
| Revenue Next Year | $17.04 | $34.24 |
| P/E Ratio | $37.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.44 | $3.50 |
| 52 Week High | $25.93 | $8.40 |
| Indicator | PWP | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 50.98 |
| Support Level | $17.05 | $5.49 |
| Resistance Level | $18.97 | $6.23 |
| Average True Range (ATR) | 0.74 | 0.26 |
| MACD | 0.25 | 0.06 |
| Stochastic Oscillator | 91.21 | 94.71 |
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.